Published in Infect Immun on October 01, 1990
Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun (1992) 3.80
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev (2001) 3.25
Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev (1995) 3.12
Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J Bacteriol (1994) 3.12
Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol (1992) 3.05
The immune response to pneumococcal proteins during experimental human carriage. J Exp Med (2002) 3.03
Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun (1994) 3.01
PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun (1991) 2.96
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol (1992) 2.80
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun (2001) 2.68
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun (1996) 2.64
Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. Infect Immun (1994) 2.51
Characterization of the cassette containing genes for type 3 capsular polysaccharide biosynthesis in Streptococcus pneumoniae. J Exp Med (1995) 2.36
The epidemiology of pneumococcal infection in children in the developing world. Philos Trans R Soc Lond B Biol Sci (1999) 2.17
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
Identification of pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus pneumoniae. Infect Immun (1999) 1.94
PspC, a pneumococcal surface protein, binds human factor H. Infect Immun (2001) 1.92
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun (2006) 1.80
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun (2003) 1.70
Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB x NZW)F1 mice. J Exp Med (1992) 1.67
Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun (2003) 1.54
PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun (2004) 1.53
A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect Immun (1991) 1.48
Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun (2001) 1.40
Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun (1992) 1.35
A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun (1998) 1.33
The autolysin-encoding gene (lytA) of Streptococcus pneumoniae displays restricted allelic variation despite localized recombination events with genes of pneumococcal bacteriophage encoding cell wall lytic enzymes. Infect Immun (1999) 1.31
Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis (2001) 1.30
The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun (2000) 1.28
Essential role for cellular phosphoglucomutase in virulence of type 3 Streptococcus pneumoniae. Infect Immun (2001) 1.27
Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes. Infect Immun (1996) 1.27
Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun (1997) 1.24
Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun (2007) 1.23
Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect Immun (2005) 1.22
Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun (2010) 1.22
Evidence of recombination and an antigenically diverse immunoglobulin A1 protease among strains of Streptococcus pneumoniae. Infect Immun (1995) 1.16
Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun (2003) 1.15
The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun (2010) 1.14
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog (2007) 1.13
Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infect Immun (2002) 1.10
Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun (2003) 1.09
PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun (2009) 1.09
CcpA-dependent and -independent control of beta-galactosidase expression in Streptococcus pneumoniae occurs via regulation of an upstream phosphotransferase system-encoding operon. J Bacteriol (2007) 1.08
Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun (2001) 1.07
Immune responses to specific antigens of Streptococcus pneumoniae and Moraxella catarrhalis in the respiratory tract. Infect Immun (2000) 1.03
Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun (2005) 1.00
Effects of zinc deficiency and pneumococcal surface protein a immunization on zinc status and the risk of severe infection in mice. Infect Immun (2003) 0.99
PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun (2005) 0.95
The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol (2012) 0.95
Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein a provides insight into microbial defense mechanism. J Mol Biol (2007) 0.95
Rapid expansion of the physical and genetic map of the chromosome of Clostridium perfringens CPN50. J Bacteriol (1995) 0.94
Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun (2002) 0.94
Lipoteichoic acid is important in innate immune responses to gram-positive bacteria. Infect Immun (2007) 0.93
Distribution and genetic diversity of the ABC transporter lipoproteins PiuA and PiaA within Streptococcus pneumoniae and related streptococci. J Bacteriol (2006) 0.91
Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis. Infect Immun (2003) 0.91
Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in finland who had acute otitis media or were nasopharyngeal carriers. Clin Vaccine Immunol (2008) 0.91
Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun (2013) 0.87
Characterization of hemin binding activity of Streptococcus pneumoniae. Infect Immun (1997) 0.86
PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clin Vaccine Immunol (2012) 0.84
Natural materno-fetal transfer of antibodies to PspA and to PsaA. Clin Exp Immunol (2004) 0.84
A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens. J Pediatr Pharmacol Ther (2016) 0.83
Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media. Int J Pediatr Otorhinolaryngol (2014) 0.83
A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Vaccine (2013) 0.83
Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response. Clin Vaccine Immunol (2013) 0.83
Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies. Clin Vaccine Immunol (2014) 0.81
Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine. Clin Vaccine Immunol (2013) 0.81
Pneumococcal phosphorylcholine esterase, Pce, contains a metal binuclear center that is essential for substrate binding and catalysis. Protein Sci (2005) 0.80
Choline Binding Proteins from Streptococcus pneumoniae: A Dual Role as Enzybiotics and Targets for the Design of New Antimicrobials. Antibiotics (Basel) (2016) 0.79
Immunoblotting in the diagnosis of culture negative endocarditis caused by streptococci and enterococci. J Clin Pathol (1995) 0.79
Pneumococcal and influenza vaccination: current situation and future prospects. Thorax (2002) 0.79
Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A. Clin Vaccine Immunol (2013) 0.78
C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal Vaccine. PLoS One (2015) 0.78
Pneumococal Surface Protein A (PspA) Regulates Programmed Death Ligand 1 Expression on Dendritic Cells in a Toll-Like Receptor 2 and Calcium Dependent Manner. PLoS One (2015) 0.77
Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice. Ther Adv Vaccines (2017) 0.75
Towards Identifying Protective B-Cell Epitopes: The PspA Story. Front Microbiol (2017) 0.75
A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia. J Infect Dis (2015) 0.75
Nanogel-based nasal ghrelin vaccine prevents obesity. Mucosal Immunol (2017) 0.75
Identification of glycosylated regions in pneumococcal PspA conjugated to serotype 6B capsular polysaccharide. Glycoconj J (2014) 0.75
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev (1989) 7.80
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974. J Clin Microbiol (1977) 3.37
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
Identification of a 16,600-dalton outer membrane protein on nontypeable Haemophilus influenzae as a target for human serum bactericidal antibody. J Clin Invest (1986) 2.91
Pneumococcal polysaccharide immunization in infants and children. Pediatrics (1978) 2.67
Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis (1986) 2.19
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog (1986) 1.64
Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae. Microb Pathog (1990) 1.53
Pneumococcal vaccine: development and prospects. Am J Med (1979) 1.51
Protein serotyping of Streptococcus pneumoniae based on reactivity to six monoclonal antibodies. Microb Pathog (1988) 1.25
Somatic antigens of Haemophilus influenzae as vaccine components. Pediatr Infect Dis J (1989) 1.08
A simple method for estimating the probable numbers of different antibodies by examining the repeat frequencies of sequences or isoelectric focusing patterns. Mol Immunol (1981) 1.04
Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis (1980) 7.45
Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med (1981) 6.45
Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun (1989) 5.23
Subclass restriction of murine anti-carbohydrate antibodies. J Immunol (1978) 4.99
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Genetic analysis of the low calcium response in Yersinia pestis mu d1(Ap lac) insertion mutants. J Bacteriol (1984) 3.90
ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes. J Immunol Methods (1979) 3.84
Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun (1992) 3.80
Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis (1992) 3.52
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol (1992) 3.05
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun (1991) 2.96
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Transformation of encapsulated Streptococcus pneumoniae. J Bacteriol (1986) 2.82
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol (1992) 2.80
Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med (1982) 2.79
Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis (2001) 2.71
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun (2001) 2.55
Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. Infect Immun (1994) 2.51
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Isolation and characterization of Ca2+-blind mutants of Yersinia pestis. J Bacteriol (1985) 2.49
Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog (1997) 2.41
Temperature-controlled plasmid regulon associated with low calcium response in Yersinia pestis. J Bacteriol (1986) 2.37
Characterization of the cassette containing genes for type 3 capsular polysaccharide biosynthesis in Streptococcus pneumoniae. J Exp Med (1995) 2.36
Reprint request reflexes. Nature (1970) 2.36
Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis (1998) 2.27
Anti-DNA autoantibodies in (NZB X NZW)F1 mice are clonally heterogeneous, but the majority share a common idiotype. J Immunol (1982) 2.25
Heterogeneity among strains and a high rate of variation within strains of a major surface antigen of Mycoplasma pulmonis. Infect Immun (1988) 2.21
Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog (1994) 2.20
Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis (1986) 2.19
Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun (1982) 2.19
Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature (1981) 2.16
Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis (2000) 2.11
PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine (1996) 2.08
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine (2000) 2.07
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect Immun (1995) 2.01
Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine (2000) 2.00
Anorectal and vaginal carriage of group B streptococci during pregnancy. J Infect Dis (1982) 1.97
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis (1996) 1.97
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
PspC, a pneumococcal surface protein, binds human factor H. Infect Immun (2001) 1.92
Group B streptococcal carriage and disease: a 6-year prospective study. J Pediatr (1987) 1.87
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Azithromycin prophylaxis during a hospital outbreak of Mycoplasma pneumoniae pneumonia. J Infect Dis (2001) 1.85
Plasmid-determined cytotoxicity in Yersinia pestis and Yersinia pseudotuberculosis. Infect Immun (1986) 1.83
IgG anti-DNA autoantibodies within an individual autoimmune mouse are the products of clonal selection. J Immunol (1989) 1.81
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol (1982) 1.77
The ability of Salmonella typhimurium to produce the siderophore enterobactin is not a virulence factor in mouse typhoid. Infect Immun (1985) 1.77
Genetic and molecular characterization of capsular polysaccharide biosynthesis in Streptococcus pneumoniae type 3. Mol Microbiol (1994) 1.77
The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol (2001) 1.77
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
Serotypes of Streptococcus pneumoniae causing disease. J Infect Dis (1979) 1.72
Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. J Immunol (1984) 1.72
The primary effect of the Ity locus is on the rate of growth of Salmonella typhimurium that are relatively protected from killing. J Immunol (1990) 1.71
Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis (1988) 1.70
The IS1167 insertion sequence is a phylogenetically informative marker among isolates of serotype 6B Streptococcus pneumoniae. J Mol Evol (1998) 1.68
PspA and PspC: their potential for use as pneumococcal vaccines. Microb Drug Resist (1997) 1.67
Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production. Infect Immun (1997) 1.67
Epidemiologic studies of Streptococcus pneumoniae in infants. The effects of season and age on pneumococcal acquisition and carriage in the first 24 months of life. Am J Epidemiol (1982) 1.65
Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog (1986) 1.64
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol (1995) 1.61
Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun (1996) 1.60
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model. Microb Pathog (1997) 1.55
Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae. Microb Pathog (1990) 1.53
Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation. Nat Med (1997) 1.53
Isolation of a prokaryotic metallothionein locus and analysis of transcriptional control by trace metal ions. Mol Microbiol (1993) 1.52
Genetic control of the susceptibility to pneumococcal infection. Curr Top Microbiol Immunol (1986) 1.50
A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect Immun (1991) 1.48
Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J Immunol (1984) 1.48
Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb Pathog (1992) 1.48
Streptococcus pyogenes pharyngitis: characterization of strains by multilocus enzyme genotype, M and T protein serotype, and pyrogenic exotoxin gene probing. J Clin Microbiol (1992) 1.47
Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine. J Clin Microbiol (1983) 1.45
A 'safe-site' for Salmonella typhimurium is within splenic polymorphonuclear cells. Microb Pathog (1992) 1.44
SmtB is a metal-dependent repressor of the cyanobacterial metallothionein gene smtA: identification of a Zn inhibited DNA-protein complex. Nucleic Acids Res (1993) 1.44